Converting blood coagulation factor IXa into factor Xa: dramatic increase in amidolytic activity identifies important...

Area of Science:

• Biochemistry
• Molecular Biology
• Enzymology

Background:

• Coagulation factors IXa (fIXa) and Xa (fXa) share structural and functional similarities.
• fIXa displays significantly lower amidolytic activity (10^4-fold) than fXa.
• Understanding the determinants of fIXa's low reactivity is crucial for potential therapeutic applications.

Purpose of the Study:

• To identify the structural determinants responsible for the low amidolytic activity of coagulation factor IXa (fIXa).
• To engineer fIXa variants with enhanced reactivity and fXa-like properties.

Main Methods:

• Expression of truncated variants of fIXa (rf9a) and fXa (rf10a) in Escherichia coli.
• Determination of crystal structures of fIXa and fXa.
• Site-directed mutagenesis to exchange active site components between rf9a and rf10a.
• Assay of amidolytic activity and substrate selectivity of engineered variants.

Main Results:

• Exchanging the 99 loop of fIXa dramatically increased its reactivity.
• Combining four specific mutations, mimicking fXa residues, resulted in a 130-fold increase in fIXa amidolytic activity.
• Engineered fIXa variants exhibited fXa substrate selectivity.
• Narrowed S3/S4 subsite and distorted S1 subsite were identified as key defects in fIXa's poor reactivity.

Conclusions:

• The poor reactivity of fIXa stems from a narrowed S3/S4 subsite and a distorted S1 subsite.
• Introducing fXa residues into fIXa can repair these defects, significantly enhancing activity and altering substrate specificity.
• Engineered coagulation enzymes hold promise for diagnostic and therapeutic development.